Advances in therapeutic drug monitoring of infliximab in pediatric inflammatory bowel disease
10.3760/cma.j.issn.1673-4408.2024.04.003
- VernacularTitle:炎症性肠病患儿英夫利西单抗的治疗药物监测研究进展
- Author:
Siqi LIU
1
;
Lingfen XU
Author Information
1. 中国医科大学附属盛京医院小儿消化内科，沈阳 110004刘斯琦现在西南医科大学附属天府医院儿科，眉山 620000
- Keywords:
Child;
Infliximab;
Inflammatory bowel disease;
Therapeutic drug monitoring;
Blood drug concentration
- From:
International Journal of Pediatrics
2024;51(4):225-230
- CountryChina
- Language:Chinese
-
Abstract:
Infliximab（IFX）is one of anti-tumor necrosis factor-α（anti-TNF-α）and is currently biological preparations with indications for the use of inflammatory bowel disease（IBD）of children in China.With the clinical application of IFX，the treatment goal of IBD has shifted from clinical remission to mucosal healing，thereby further improving the prognosis of the disease.However，in clinical work，it has been found that some children have primary or secondary unresponsiveness to IFX treatment，which is a major challenge during the IFX treatment process.Research has found that this phenomenon may be related to a decrease in blood drug concentration and the production of anti drug antibodies.Therefore，IFX therapeutic drug monitoring（TDM）is very important in the treatment of pediatric IBD.This article reviews the current application status of TDM in the treatment of IBD in children with IFX，and puts forward prospects for future research directions of TDM.
